FDA: Breast implants linked to rare forms of cancer
September 10, 2022, 8:00 pm

FDA: Breast implants linked to rare forms of cancer

Health care providers and people with implants have been urged to report all cases of SCC, lymphomas or any other cancers found around the breast implant to the FDA.

The US Food and Drug Administration (FDA) has issued a public alert warning that rare types of cancer have been linked to breast implant surgeries, according to the RT.

In a report published on Thursday the FDA said it had found that certain cancers such as squamous cell carcinoma (SCC) and various lymphomas have been reported in the scar tissue that forms around breast implants.

The agency notes that although the occurrence of these cancers in the capsule around breast implants is rare, healthcare providers and people looking to receive the surgery should be aware of the risks and report any cases of cancer found around the implant.

The FDA also states that these new lymphomas are something the agency has learned about only recently through postmarket review of breast implants and are not the same as the previously reported breast implant-associated anaplastic large cell lymphoma.

A preliminary review of published literature revealed fewer than 20 cases of SCC and fewer than 30 cases of various lymphomas in the scar tissue around the breast implant, the agency noted.

The US Food and Drug Administration (FDA) has issued a public alert warning that rare types of cancer have been linked to breast implant surgeries - Photo. Pixabay

It’s noted that people with breast implants do not need to change their routine medical care or rush to remove their implants in light of this announcement, but they should be aware of some of the reported signs and symptoms, which include swelling, pain, lumps or changes in the skin.

The FDA states that the exact incidence rate and risk factors of these newly reported cancers remain unknown and that “this is an emerging issue and our understanding is evolving.”

J&J to end global sales of talc-based baby powder after cancer lawsuits

Health care providers and people with implants have been urged to report all cases of SCC, lymphomas or any other cancers found around the breast implant to the FDA.

Last year, the FDA introduced several updates to breast implant regulations, including new labeling with a boxed warning and a patient checklist that informs people that implants are not a medical device that will last a lifetime.

Doctors are also now required to walk patients through all the potential health problems derived from breast implant surgery.

Source: rt

Albania reports 2nd cyberattack by Iran, on border systems Official historic ceremonies Charles III as the new king of Britain

BENEFIT, the Kingdom’s innovator and leading company in Fintech and electronic financial transactions service, held its Annual General Meeting (AGM) at the company’s headquarters in the Seef District.
During the meeting, shareholders approved all items listed on the agenda, including the ratification of the minutes of the previous AGM held on 26 March 2024. The session reviewed and approved the Board’s Annual Report on the company’s activities and financial performance for the fiscal year ended 31 December 2024, and the shareholders expressed their satisfaction with the company’s operational and financial results during the reporting period.
The meeting also reviewed the Independent External Auditor’s Report on the company’s consolidated financial statements for the year ended 31 December 2024. Subsequently, the shareholders approved the audited financial statements for the fiscal year. Based on the Board’s recommendation, the shareholders approved the distribution of a cash dividend equivalent to 10% of the paid-up share capital.
Furthermore, the shareholders endorsed the allocation of a total amount of BD 172,500 as remuneration to the members of the Board for the year ended 31 December 2024, subject to prior clearance by related authorities.
The extension of the current composition of the Board was approved, which includes ten members and one CBB observer, for a further six-month term, expiring in September 2025, pending no objection from the CBB.
The meeting reviewed and approved the Corporate Governance Report for 2024, which affirmed the company’s full compliance with the corporate governance directives issued by the CBB and other applicable regulatory frameworks. The AGM absolved the Board Members of liability for any of their actions during the year ending on 31st December 2024, in accordance with the Commercial Companies Law.
In alignment with regulatory requirements, the session approved the reappointment of Ernst & Young (EY) as the company’s External Auditors for the fiscal year 2025, covering both the parent company and its subsidiaries—Sinnad and Bahrain FinTech Bay. The Board was authorised to determine the external auditors’ professional fees, subject to approval from the CBB, and the meeting concluded with a discussion of any additional issues as per Article (207) of the Commercial Companies Law.
Speaking on the company’s performance, Mr. Mohamed Al Bastaki, Chairman BENEFIT , stated: “In terms of the financial results for 2024, I am pleased to say that the year gone by has also been proved to be a success in delivering tangible results. Growth rate for 2024 was 19 per cent. Revenue for the year was BD 17 M (US$ 45.3 Million) and net profit was 2 Million ($ 5.3 Million).

Mr. Al Bastaki also announced that the Board had formally adopted a new three-year strategic roadmap to commence in 2025. The strategy encompasses a phased international expansion, optimisation of internal operations, enhanced revenue diversification, long-term sustainability initiatives, and the advancement of innovation and digital transformation initiatives across all service lines.
“I extend my sincere appreciation to the CBB for its continued support of BENEFIT and its pivotal role in fostering a stable and progressive regulatory environment for the Kingdom’s banking and financial sector—an environment that has significantly reinforced Bahrain’s standing as a leading financial hub in the region,” said Mr. Al Bastaki. “I would also like to thank our partner banks and valued customers for their trust, and our shareholders for their ongoing encouragement. The achievements of 2024 set a strong precedent, and I am confident they will serve as a foundation for yet another successful and impactful year ahead.”
Chief Executive of BENEFIT; Mr. Abdulwahed AlJanahi commented, “The year 2024 represented another pivotal chapter in BENEFIT ’s evolution. We achieved substantial progress in advancing our digital strategy across multiple sectors, while reinforcing our long-term commitment to the development of Bahrain’s financial services and payments landscape. Throughout the year, we remained firmly aligned with our objective of delivering measurable value to our shareholders, strategic partners, and customers. At the same time, we continued to play an active role in enabling Bahrain’s digital economy by introducing innovative solutions and service enhancements that directly address market needs and future opportunities.”
Mr. AlJanahi affirmed that BENEFIT has successfully developed a robust and well-integrated payment network that connects individuals and businesses across Bahrain, accelerating the adoption of emerging technologies in the banking and financial services sector and reinforcing Bahrain’s position as a growing fintech hub, and added, “Our achievements of the past year reflect a long-term vision to establish a resilient electronic payment infrastructure that supports the Kingdom’s digital economy. Key developments in 2024 included the implementation of central authentication for open banking via BENEFIT Pay”
Mr. AlJanahi concluded by thanking the Board for its strategic direction, the company’s staff for their continued dedication, and the Central Bank of Bahrain, member banks, and shareholders for their valuable partnership and confidence in the company’s long-term vision.